Cargando…
Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
SIMPLE SUMMARY: Immune therapy using checkpoint inhibitors has been increasing in genitourinary cancers for the past decade, starting with monotherapy in renal cell carcinoma and urothelial carcinoma to now include many first-line combinations. More combinations and FDA/EMA indications are undoubted...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139183/ https://www.ncbi.nlm.nih.gov/pubmed/35626064 http://dx.doi.org/10.3390/cancers14102460 |